Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
This was a retrospective cohort study using Truven Health Analytics' MarketScan Commercial Claims and Encounters and Medicare Supplement and Coordination of Benefit administrative claims databases. The analysis was conducted using the most recent 5 years of data from the database, 01 January 2015, to 28 February 2021 (study period). Included patients were followed for outcome evaluation from the index date (first prescription of treatment, immunotherapy \[IO\] or targeted therapy \[TT\] following diagnosis of non-metastatic malignant melanoma and evidence of first lymph node resection), until the first occurrence of end of continuous eligibility or end of the study period.
Melanoma
Percentage of patients with adverse events (AEs) following first systemic adjuvant therapy, Up to 5 years
Percentage of patients with AEs following first systemic adjuvant therapy completion/discontinuation, Up to 5 years|Healthcare resource utilization (HCRU) associated with AEs following first systemic adjuvant therapy, 30 days|Healthcare costs associated with AEs following first systemic adjuvant therapy, 30 days|HCRU associated with AEs following first systemic adjuvant therapy completion/discontinuation, 30 days|Healthcare costs associated with AEs following first systemic adjuvant therapy completion/discontinuation, 30 days
This was a retrospective cohort study using Truven Health Analytics' MarketScan Commercial Claims and Encounters and Medicare Supplement and Coordination of Benefit administrative claims databases. The analysis was conducted using the most recent 5 years of data from the database, 01 January 2015, to 28 February 2021 (study period). Included patients were followed for outcome evaluation from the index date (first prescription of treatment, immunotherapy \[IO\] or targeted therapy \[TT\] following diagnosis of non-metastatic malignant melanoma and evidence of first lymph node resection), until the first occurrence of end of continuous eligibility or end of the study period.